Survivin: A novel neuroendocrine marker for pheochromocytoma

Christian A. Koch, Alexander Vortmeyer, Raihanatou Diallo, Christopher Poremba, Thomas J. Giordano, Donita Sanders, Stefan R. Bornstein, George P. Chrousos, Karel Pacak

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objective: To study survivin expression in human adrenal medulla and in benign and malignant pheochromocytoma tissue as a tool to predict tumor metastatic potential and prognosis. Design: Blinded study to assess the role of the anti-survivin antibody in chromaffin cells. Methods: We performed immunohistochemistry with a purified rabbit-polyclonal anti-survivin anti-body on 39 formalin-fixed and paraffin-embedded pheochromocytoma/paraganglioma specimens, and on 10 normal adrenal medulla samples from patients unaffected by a chromaffin cell tumor. Fourteen samples were from 14 patients with benign pheochromocytoma (<8 year follow-up, mean 5.2 years), 18 specimens were from 12 patients with malignant pheochromocytoma (<13 year follow-up, mean 6.3 years), 5 samples were from 2 patients with malignant paraganglioma (<6 year follow-up, mean 4 years), and 2 specimens from 2 patients with benign paraganglioma (<7 year follow-up, mean 5.5 years). Malignancy was defined by metastases in non-chromaffin tissues. Staining intensity with the anti-survivin antibody was scored from 0 (none) to 3+ (heavy). Tissues from human kidney, breast, and melanoma served as controls. Results: All pheochromocytoma/paraganglioma specimens stained either 2+ or 3+. By analysis of variance (ANOVA), there was no statistically significant difference between the staining intensity of benign and malignant samples. All normal adrenal medulla specimens stained positively with anti-survivin but to a lesser degree than the chromaffin cell tumors (P < 0.01). Conclusions: Based on these findings, we conclude that (i) survivin may represent a novel neuroendocrine marker for chromaffin cell tumors, and (ii) survivin does not appear to reliably distinguish benign from malignant pheochromocytomas/paragangliomas and thus does not identify patients at risk of recurrent disease.

Original languageEnglish (US)
Pages (from-to)381-388
Number of pages8
JournalEuropean Journal of Endocrinology
Volume146
Issue number3
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Pheochromocytoma
Paraganglioma
Chromaffin Cells
Adrenal Medulla
Neoplasms
Anti-Idiotypic Antibodies
Staining and Labeling
Paraffin
Formaldehyde
Melanoma
Analysis of Variance
Breast
Immunohistochemistry
Neoplasm Metastasis
Rabbits
Kidney

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Koch, C. A., Vortmeyer, A., Diallo, R., Poremba, C., Giordano, T. J., Sanders, D., ... Pacak, K. (2002). Survivin: A novel neuroendocrine marker for pheochromocytoma. European Journal of Endocrinology, 146(3), 381-388. https://doi.org/10.1530/eje.0.1460381

Survivin : A novel neuroendocrine marker for pheochromocytoma. / Koch, Christian A.; Vortmeyer, Alexander; Diallo, Raihanatou; Poremba, Christopher; Giordano, Thomas J.; Sanders, Donita; Bornstein, Stefan R.; Chrousos, George P.; Pacak, Karel.

In: European Journal of Endocrinology, Vol. 146, No. 3, 01.01.2002, p. 381-388.

Research output: Contribution to journalArticle

Koch, CA, Vortmeyer, A, Diallo, R, Poremba, C, Giordano, TJ, Sanders, D, Bornstein, SR, Chrousos, GP & Pacak, K 2002, 'Survivin: A novel neuroendocrine marker for pheochromocytoma', European Journal of Endocrinology, vol. 146, no. 3, pp. 381-388. https://doi.org/10.1530/eje.0.1460381
Koch, Christian A. ; Vortmeyer, Alexander ; Diallo, Raihanatou ; Poremba, Christopher ; Giordano, Thomas J. ; Sanders, Donita ; Bornstein, Stefan R. ; Chrousos, George P. ; Pacak, Karel. / Survivin : A novel neuroendocrine marker for pheochromocytoma. In: European Journal of Endocrinology. 2002 ; Vol. 146, No. 3. pp. 381-388.
@article{c8a3c3c02658415cb1adcf112c1fe0d1,
title = "Survivin: A novel neuroendocrine marker for pheochromocytoma",
abstract = "Objective: To study survivin expression in human adrenal medulla and in benign and malignant pheochromocytoma tissue as a tool to predict tumor metastatic potential and prognosis. Design: Blinded study to assess the role of the anti-survivin antibody in chromaffin cells. Methods: We performed immunohistochemistry with a purified rabbit-polyclonal anti-survivin anti-body on 39 formalin-fixed and paraffin-embedded pheochromocytoma/paraganglioma specimens, and on 10 normal adrenal medulla samples from patients unaffected by a chromaffin cell tumor. Fourteen samples were from 14 patients with benign pheochromocytoma (<8 year follow-up, mean 5.2 years), 18 specimens were from 12 patients with malignant pheochromocytoma (<13 year follow-up, mean 6.3 years), 5 samples were from 2 patients with malignant paraganglioma (<6 year follow-up, mean 4 years), and 2 specimens from 2 patients with benign paraganglioma (<7 year follow-up, mean 5.5 years). Malignancy was defined by metastases in non-chromaffin tissues. Staining intensity with the anti-survivin antibody was scored from 0 (none) to 3+ (heavy). Tissues from human kidney, breast, and melanoma served as controls. Results: All pheochromocytoma/paraganglioma specimens stained either 2+ or 3+. By analysis of variance (ANOVA), there was no statistically significant difference between the staining intensity of benign and malignant samples. All normal adrenal medulla specimens stained positively with anti-survivin but to a lesser degree than the chromaffin cell tumors (P < 0.01). Conclusions: Based on these findings, we conclude that (i) survivin may represent a novel neuroendocrine marker for chromaffin cell tumors, and (ii) survivin does not appear to reliably distinguish benign from malignant pheochromocytomas/paragangliomas and thus does not identify patients at risk of recurrent disease.",
author = "Koch, {Christian A.} and Alexander Vortmeyer and Raihanatou Diallo and Christopher Poremba and Giordano, {Thomas J.} and Donita Sanders and Bornstein, {Stefan R.} and Chrousos, {George P.} and Karel Pacak",
year = "2002",
month = "1",
day = "1",
doi = "10.1530/eje.0.1460381",
language = "English (US)",
volume = "146",
pages = "381--388",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "3",

}

TY - JOUR

T1 - Survivin

T2 - A novel neuroendocrine marker for pheochromocytoma

AU - Koch, Christian A.

AU - Vortmeyer, Alexander

AU - Diallo, Raihanatou

AU - Poremba, Christopher

AU - Giordano, Thomas J.

AU - Sanders, Donita

AU - Bornstein, Stefan R.

AU - Chrousos, George P.

AU - Pacak, Karel

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Objective: To study survivin expression in human adrenal medulla and in benign and malignant pheochromocytoma tissue as a tool to predict tumor metastatic potential and prognosis. Design: Blinded study to assess the role of the anti-survivin antibody in chromaffin cells. Methods: We performed immunohistochemistry with a purified rabbit-polyclonal anti-survivin anti-body on 39 formalin-fixed and paraffin-embedded pheochromocytoma/paraganglioma specimens, and on 10 normal adrenal medulla samples from patients unaffected by a chromaffin cell tumor. Fourteen samples were from 14 patients with benign pheochromocytoma (<8 year follow-up, mean 5.2 years), 18 specimens were from 12 patients with malignant pheochromocytoma (<13 year follow-up, mean 6.3 years), 5 samples were from 2 patients with malignant paraganglioma (<6 year follow-up, mean 4 years), and 2 specimens from 2 patients with benign paraganglioma (<7 year follow-up, mean 5.5 years). Malignancy was defined by metastases in non-chromaffin tissues. Staining intensity with the anti-survivin antibody was scored from 0 (none) to 3+ (heavy). Tissues from human kidney, breast, and melanoma served as controls. Results: All pheochromocytoma/paraganglioma specimens stained either 2+ or 3+. By analysis of variance (ANOVA), there was no statistically significant difference between the staining intensity of benign and malignant samples. All normal adrenal medulla specimens stained positively with anti-survivin but to a lesser degree than the chromaffin cell tumors (P < 0.01). Conclusions: Based on these findings, we conclude that (i) survivin may represent a novel neuroendocrine marker for chromaffin cell tumors, and (ii) survivin does not appear to reliably distinguish benign from malignant pheochromocytomas/paragangliomas and thus does not identify patients at risk of recurrent disease.

AB - Objective: To study survivin expression in human adrenal medulla and in benign and malignant pheochromocytoma tissue as a tool to predict tumor metastatic potential and prognosis. Design: Blinded study to assess the role of the anti-survivin antibody in chromaffin cells. Methods: We performed immunohistochemistry with a purified rabbit-polyclonal anti-survivin anti-body on 39 formalin-fixed and paraffin-embedded pheochromocytoma/paraganglioma specimens, and on 10 normal adrenal medulla samples from patients unaffected by a chromaffin cell tumor. Fourteen samples were from 14 patients with benign pheochromocytoma (<8 year follow-up, mean 5.2 years), 18 specimens were from 12 patients with malignant pheochromocytoma (<13 year follow-up, mean 6.3 years), 5 samples were from 2 patients with malignant paraganglioma (<6 year follow-up, mean 4 years), and 2 specimens from 2 patients with benign paraganglioma (<7 year follow-up, mean 5.5 years). Malignancy was defined by metastases in non-chromaffin tissues. Staining intensity with the anti-survivin antibody was scored from 0 (none) to 3+ (heavy). Tissues from human kidney, breast, and melanoma served as controls. Results: All pheochromocytoma/paraganglioma specimens stained either 2+ or 3+. By analysis of variance (ANOVA), there was no statistically significant difference between the staining intensity of benign and malignant samples. All normal adrenal medulla specimens stained positively with anti-survivin but to a lesser degree than the chromaffin cell tumors (P < 0.01). Conclusions: Based on these findings, we conclude that (i) survivin may represent a novel neuroendocrine marker for chromaffin cell tumors, and (ii) survivin does not appear to reliably distinguish benign from malignant pheochromocytomas/paragangliomas and thus does not identify patients at risk of recurrent disease.

UR - http://www.scopus.com/inward/record.url?scp=0036207949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036207949&partnerID=8YFLogxK

U2 - 10.1530/eje.0.1460381

DO - 10.1530/eje.0.1460381

M3 - Article

C2 - 11888845

AN - SCOPUS:0036207949

VL - 146

SP - 381

EP - 388

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 3

ER -